After ovarian cancer flop, PharmaMar's lurbinectedin makes the cut in small cell lung cancer

More than a year after its experimental drug, lurbinectedin, failed a late-stage test in platinum-resistant ovarian cancer patients, Spanish biotech PharmaMar on Monday said the agent met the main goal in patients with relapsed small cell lung cancer (SCLC) in a Phase II study.